Reports
Global Diabetic Neuropathy Treatment Market Share, Trends, Growth, Analysis, Insights, Forecast: By Disease Type: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy; By Treatment Method: Drugs, Others; By End User; By Treatment Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2023-2031
Global Diabetic Neuropathy Treatment Market Outlook
The global diabetic neuropathy treatment market is driven by the rising number of hyperglycaemia cases, which was nearly 553 million in 2022. The prevalence of the hyperglycaemia is likely to grow at a CAGR of 3% during the forecast period of 2023-2031 to reach approximately 725 million cases by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Introduction
Diabetic neuropathy is a condition that causes nerve damage in people with diabetes. Nerves are damaged by high blood sugar in diabetics, resulting in diabetic neuropathy.
Legs and feet are the most severely affected body parts in this condition.
There are also symptoms associated with neuropathy, such as pain and numbness, depending on the nerves affected, such as peripheral nerves, autonomic nerves, proximal nerves, and focal nerves.
Following are the different types of diabetic neuropathy:
- Peripheral Neuropathy- Affects legs and feet.
- Autonomic Neuropathy- Affects the digestive system, primarily the stomach.
- Proximal Neuropathy- Affects buttocks and thighs.
Worldwide, diabetes treatment is considered a top priority. It is not possible to cure neuropathic changes or provide pain relief with a single treatment. Various approaches are used to manage diabetic neuropathy, including intensive glucose control, treatment of risk factors, and treatment based on pathogenetic mechanisms.
The rapidly rising number of diabetic neuropathies and increased awareness in the next few years will compel major companies to launch new products. Thus, key players in the market are developing technologically advanced products to gain a competitive edge.
According to the global diabetic neuropathy treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Disease Type
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
Market Breakup by Treatment Method
- Drugs
- Analgesics
- Antidepressant
- Anticonvulsants
- Others
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Non-Steroidal Anti-Inflammatory Drugs
- Others
Diabetic Neuropathy Treatment Market Breakup by End-User
- Hospitals And Clinics
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Prevalence of Diabetes to Drive the Diabetic Neuropathy Treatment Market Growth
The steep rise in diabetes cases will impact the growth of the market during the forecast period. The complications related to diabetes, cardiovascular diseases, obesity, and other complications related to glucose control contribute to neuropathy development. This includes the development of new products by manufacturers that are effective at treating neuropathy.
Additionally, increased urbanization is causing unhealthy lifestyles like unhealthy food consumption, sedentary living, and others that adversely affect the market growth.
Other factors driving the growth of the diabetic neuropathy treatment market include ageing population, growing health care facilities, and increasing health care costs.
Market Growth to be Hindered by the High Price of the Product and the Availability of Alternatives for Diabetic Neuropathy
Diabetes neuropathy drugs are becoming increasingly expensive, and alternative treatments for the condition are also available readily available. These factors are hindering the growth of the global market.
Availability of alternative treatments, such as radiotherapy and physical therapy, that may improve patient outcomes, is also obstructing the growth of the market. Other factors that could hamper the market growth include regulations, product recalls, and FDA approval delays.
Regional Outlook for the Diabetic Neuropathy Treatment Market
The increasing diabetes prevalence and incidence cases make North America a major regional market. Various factors contribute to the growth of the market, such as early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.
It is estimated that the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to the high prevalence of diabetes, obesity, and cardiac arrhythmia-related issues, and government support for healthcare awareness and research activities.
Therapeutic Landscape
People with diabetes can be affected by diabetic neuropathy, a chronic debilitating condition. The objective assessment of diabetic neuropathy makes it difficult to diagnose and evaluate in clinical trials. Currently, there is no treatment available to prevent or reverse neuropathy or to relieve pain completely.
Diabetic neuropathy could be treated with Nav 1.7 antagonists, calcium channel blockers, anti-NGF antibodies, and angiotensin II type 2 receptor antagonists.
As part of its neuropathic pain treatment program, Novartis AG introduced Tegerton (carbamazepine), a new epilepsy drug designed to reduce nerve impulses that cause pain in diabetics.
Nucynta ER, a pain reliever derived from opioids, used to treat diabetes-induced nerve damage, was also launched by Janssen Pharmaceuticals.
Among the recommended treatment options for diabetic neuropathy, there are antidepressants like amitriptyline and duloxetine as well as topical agents like gabapentin and pregabalin analogues and opioids for pain relief in neuropathy.
In order to alleviate pain and improve quality of life associated with diabetic neuropathy, more research is needed on the most effective drugs or combinations.
Clinical Trials
In current therapies, sensory deficits and aetiology are not addressed, so there is an unmet demand for treatment options that target the natural course of the condition.
The outcomes of recent randomized controlled trials show that some of these pathological treatments improve neuropathic endpoints clinically. Patients with neuropathic pain remain undertreated with effective analgesic monotherapy as limited number of patients able to achieve clinically meaningful results.
New pharmaceutical approaches have been expanded due to increased knowledge of neurobiology and phenotypic profiling of neuropathic pain.
A number of promising molecular structures are in clinical development, which will soon improve our therapeutic arsenal of diabetic neuropathy treatments.
In diabetic neuropathy, the disease progresses over time. Medication and lifestyle changes can alleviate this condition. Medications that control diabetes are the most effective in slowing the onset of complications caused by diabetes.
The FDA has approved these drugs for treating diabetic neuropathy:
- anticonvulsant Lyrica (pregabalin)
- antidepressant Cymbalta (duloxetine)
- opioid Nucinta (tapentadol)
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global diabetic neuropathy treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Novartis AG
- Pfizer Inc.
- Glenmark Pharmaceuticals Ltd.
- Eli Lilly and Company
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- GlaxoSmithKline Plc
- Lupin Ltd
- Depomed, Inc
- Astellas Pharma Inc
- Meda Pharma GmBH & Co. KG
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Method |
|
| Breakup by End User |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Diabetic Neuropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Diabetic Neuropathy Treatment Market
8.1 Global Diabetic Neuropathy Treatment Market Overview
8.2 Global Diabetic Neuropathy Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Diabetic Neuropathy Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Diabetic Neuropathy Treatment Market Forecast Value (2023-2031)
8.3 Global Diabetic Neuropathy Treatment Market by Disease Type
8.3.1 Market Overview
8.3.1.1 Peripheral Neuropathy
8.3.1.2 Autonomic Neuropathy
8.3.1.3 Proximal Neuropathy
8.3.1.4 Focal Neuropathy
8.4 Global Diabetic Neuropathy Treatment Market by Treatment Method
8.4.1 Market Overview
8.4.1.1 Drugs
8.4.1.1.1 Analgesics
8.4.1.1.2 Antidepressant
8.4.1.1.3 Anticonvulsants
8.4.1.1.4 Others
8.4.1.2 Transcutaneous Electrical Nerve Stimulation (TENS)
8.4.1.3 Non-Steroidal Anti-Inflammatory Drugs
8.4.1.4 Others
8.5 Global Diabetic Neuropathy Treatment Market by End User
8.5.1 Market Overview
8.5.1.1 Hospitals And Clinics
8.5.1.2 Retail Pharmacy
8.5.1.3 Online Pharmacy
8.6 Global Diabetic Neuropathy Treatment Market by Treatment Channel
8.6.1 Public
8.6.2 Private
8.7 Global Diabetic Neuropathy Treatment Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 North America Diabetic Neuropathy Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Diabetic Neuropathy Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Diabetic Neuropathy Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Diabetic Neuropathy Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Diabetic Neuropathy Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Diabetic Neuropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicator
14.5 Key Price Indicator
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Novartis AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Pfizer Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Glenmark Pharmaceuticals Ltd.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Eli Lilly and Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Abbott Laboratories
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 F. Hoffmann-La Roche Ltd
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Johnson & Johnson Services, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 GlaxoSmithKline Plc
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Lupin Ltd
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Depomed, Inc
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Astellas Pharma Inc
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Meda Pharma GmBH & Co. KG
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Global Diabetic Neuropathy Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market growth is likely to be driven by the rising prevalence of Hyperglycemia, which is likely to grow at a CAGR of 3% during the forecast period of 2023-2031.
The rising cases of diabetes and launch of new products are the major factors driving the growth of the market.
North America has been leading the global market due to early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.
The high cost of the product and the availability of alternatives for diabetic neuropathy are hindering the market growth.
The four types of diabetic neuropathy are peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.
Diabetes causes nerve damage, which is known as diabetic neuropathy. Diabetes-related high blood glucose levels, also known as blood sugar, and high levels of fats in the blood, such as triglycerides, can damage nerves over time.
The signs and symptoms of peripheral neuropathy include numbness, prickling, or tingling in your feet or hands that can spread up into your legs and arms. Sharp, jabbing, throbbing, or burning discomfort Touch sensitivity to the extreme.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER